The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of common stock in Replimune Group Inc as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Both reporting persons each reported 3,115,243.18 shares of Replimune Group Inc common stock beneficially owned.
  • Percent of class: The aggregate position represents 3.3% of Replimune Group Inc's outstanding common stock.
  • Shared voting power: Both entities reported shared voting power over 3,115,199.18 shares, with sole voting power of 0.00.
  • Shared dispositive power: Both entities reported shared dispositive power over 3,115,243.18 shares, with sole dispositive power of 0.00.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Filing entity classification: The Goldman Sachs Group, Inc. is classified as a parent holding company (HC, CO); Goldman Sachs & Co. LLC is classified as a broker-dealer, investment adviser, and other (BD, OO, IA).
  • Signed by: Ameen Soetan, Attorney-in-fact, on behalf of both reporting persons, dated October 8, 2026.

Goldman Sachs Discloses Amended Passive Stake in Replimune Group

According to the amended Schedule 13G filing, The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC jointly reported beneficial ownership of 3,115,243.18 shares of Replimune Group Inc common stock (CUSIP: 76029N106), representing 3.3% of the class as of September 30, 2026. The filing is designated Amendment No. 1. Both reporting persons are located at 200 West Street, New York, NY 10282. Replimune Group Inc's principal executive offices are listed at 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801.

The filing discloses that neither reporting person holds any sole voting or sole dispositive power over the reported shares. Shared voting power is reported at 3,115,199.18 shares for both entities, while shared dispositive power is reported at 3,115,243.18 shares. According to the filing's Item 7 exhibit, the securities reported by The Goldman Sachs Group, Inc. as parent holding company "are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC," described as "a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940."

The filing further states, in accordance with SEC Release No. 34-39538, that this disclosure reflects securities beneficially owned by certain operating units collectively referred to as the "Goldman Sachs Reporting Units," and that those units "disclaim beneficial ownership of the securities beneficially owned by (i) any client accounts with respect to which the Goldman Sachs Reporting Units or their employees have voting or investment discretion or both" and "(ii) certain investment entities of which the Goldman Sachs Reporting Units act as the general partner, managing general partner or other manager, to the extent interests in such entities are held by persons other than the Goldman Sachs Reporting Units." The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

What Was Disclosed

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amended Schedule 13G disclosing combined beneficial ownership of 3,115,243.18 shares, or 3.3%, of Replimune Group Inc common stock, with a triggering event date of September 30, 2026.